Ipratropiumbromide/Salbutamol Neutec (Ipratropium Bromide, Salbutamol)

Ipratropium bromide blocks muscarinic M3 receptors on airway smooth muscle, preventing acetylcholine‑induced constriction. By reducing cholinergic tone, it helps keep the airways open. When paired with salbutamol, which stimulates β2 receptors to relax smooth muscle, the two agents produce additive bronchodilation.

The dosing regimen for Ipratropiumbromide/Salbutamol Neutec is determined by the prescribing clinician based on the patient’s condition, severity of symptoms, and response to therapy. Healthcare professionals adjust the number of inhalations and frequency according to established clinical guidelines.

Safety data for use in pregnancy and lactation are limited. The product should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Physicians should evaluate each case individually and discuss potential risks with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. The sales team will verify trade or institutional credentials, then respond with pricing, availability, shipping details and any required import documentation.

Compared with monotherapy, the ipratropium‑salbutamol combo offers complementary mechanisms that can achieve greater bronchodilation and symptom control, especially in patients who do not respond adequately to a single agent. Clinical studies show improved lung function and reduced rescue medication use versus either component alone.

Store the inhalation solution at room temperature, below 25 °C. Keep the container tightly closed, protect it from moisture and direct sunlight, and retain it in the original packaging until use to maintain product stability.

The product is intended for inhalation. It can be delivered via a nebulizer or a metered‑dose inhaler, according to the device supplied with the medication. Patients should follow the inhalation technique instructed by their healthcare provider to ensure optimal drug deposition in the lungs.

Serious adverse events include paradoxical bronchospasm, which may worsen breathing, and cardiovascular effects such as tachycardia, arrhythmia, or hypertension. If any of these occur, immediate medical attention is required and the medication should be discontinued.

The product is contraindicated in individuals with a known hypersensitivity to ipratropium, salbutamol, or any excipients. Patients with narrow‑angle glaucoma, severe urinary retention, or certain cardiac conditions should avoid use unless specifically advised by a physician.